SEC Tracker
Get the app
ORIC · XBRL financial data

Oric Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (ORIC's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
General and administrative6,2946,947*7,0307,0777,1167,600*8,0788,5157,8988,695*8,1829,000
Total operating expenses28,68231,428*28,99036,01738,31839,570*32,71839,06436,67134,551*39,61945,296
Operating income (loss)(28,682)(31,428)*(28,990)(36,017)(38,318)(39,570)*(32,718)(39,064)(36,671)(34,551)*(39,619)(45,296)
Income tax expense (benefit)—year only———year only———year only——
Net income (loss)(25,478)(28,330)*(25,011)(31,963)(34,566)(36,307)*(30,021)(36,355)(32,587)(30,505)*(35,767)(41,492)
Earnings per share, basic USD per share(0.44)(0.49)*(0.37)(0.45)(0.49)(0.51)*(0.42)(0.47)(0.33)(0.30)*(0.34)(0.38)
Earnings per share, diluted USD per share(0.44)(0.49)*(0.37)(0.45)(0.49)(0.51)*(0.42)(0.47)(0.33)(0.30)*(0.34)(0.38)
Weighted average shares, basic thousands of shares57,40257,456*67,35070,34870,54370,652*71,04178,12698,953102,586*105,473108,012
Weighted average shares, diluted thousands of shares57,40257,456*67,35070,34870,54370,652*71,04178,12698,953102,586*105,473108,012

Balance sheet

CSV

Fiscal quarters (ORIC's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents26,23823,38456,36049,83144,23059,40649,33475,86449,66845,66956,39637,483
Marketable securities201,058184,803260,418236,575228,139196,554154,389206,649237,472235,819225,536227,278
Marketable securities, non-current28,86726,85214,69422,1269,998020,03945,216125,908110,762137,779122,799
Prepaid and other current assets4,9404,4107,3058,1937,0596,2907,7108,6118,4546,9788,3018,934
Total current assets232,236212,597324,083294,599279,428262,250211,433291,124295,594288,466290,233273,695
Property and equipment, net3,0622,8622,8012,8783,0912,9243,0212,7622,5592,4152,1472,242
Right-of-use asset—9,144———8,380———6,658——
Total assets274,335252,007350,786328,906302,070274,142242,858346,857431,192408,890436,762404,685
Accounts payable3,7369442,9882,3094,2491,5485,1603,1302,9003,8242,8953,873
Accrued liabilities15,20819,51412,22217,23016,99923,29812,45714,92017,27916,59314,87616,883
Total current liabilities18,94420,45815,21019,53921,24824,84617,61718,05020,17920,41717,77120,756
Lease liability, non-current—7,461———6,174———4,111——
Total liabilities26,92127,91922,14126,50628,07631,02023,12022,86224,27324,52821,20523,429
Accumulated deficit(406,597)(434,927)(459,938)(491,901)(526,467)(562,774)(592,795)(629,150)(661,737)(692,242)(728,009)(769,501)
Total stockholders' equity247,414224,088328,645302,400273,994243,122219,738323,995406,919384,362415,557381,256
Total liabilities and equity274,335252,007350,786328,906302,070274,142242,858346,857431,192408,890436,762404,685
Common shares outstanding (cover page) thousands of shares54,55167,37667,42270,54270,56771,02771,08897,12397,389100,358103,518103,653

Cash flows

CSV

Fiscal quarters (ORIC's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(25,478)(28,330)*(25,011)(31,963)(34,566)(36,307)*(30,021)(36,355)(32,587)(30,505)*(35,767)(41,492)
Stock-based compensation3,864*3,923*4,9584,996*5,056*5,203*6,5546,574*5,631*6,278*6,8987,091*
Net cash from operating activities(19,645)*(24,270)*(30,186)(25,625)*(28,797)*(28,054)*(32,533)(30,842)*(25,112)*(22,483)*(32,438)(31,605)*
Purchases of property and equipment77*57*218333*418*219*38763*35*227*2356*
Net cash from investing activities(57,831)*20,963*(61,868)18,280*23,070*42,655*22,450(76,930)*(110,535)*16,984*(17,975)11,864*
Proceeds from issuing common stock0*226*125,0000*0*0*0133,925*110,444*0*60,8810*
Net cash from financing activities31*453*125,030816*126*575*11134,302*109,451*1,500*61,140828*
Net change in cash(77,445)*(2,854)*32,976(6,529)*(5,601)*15,176*(10,072)26,530*(26,196)*(3,999)*10,727(18,913)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Oric Pharmaceuticals37,483not reported(31,605)*103.7M12.3 quarters 10-QJun 30, 2026
Geron69,17960,19010,267*644.2M— 10-QSep 30, 2026
Intellia Therapeutics156,0987,163(85,430)*140.4M4.9 quarters 10-QSep 30, 2026
Wave Life Sciences197,31513,158(60,142)*197.2M7.4 quarters 10-QSep 30, 2026
CorMedix256,692101,93186,237*77.9M— 10-QJun 30, 2026
Niagen Bioscience69,50927,1922,625*79.2M— 10-QSep 30, 2026
Nurix Therapeutics720,242673,064615,631*109.2M— 10-QAug 31, 2026
Ardelyx46,317127,6552,171*251.4M— 10-QSep 30, 2026
Collegium Pharmaceutical144,797216,33986,536*31.1M— 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.